Previous 10 | Next 10 |
home / stock / blu:cc / blu:cc news
Biotech companies are often at the cutting edge of medical research, making them relatively risky but profitable investments. Yet, the prospects can be dramatically different for each biotech company. Many new ventures fail even before entering the market, resulting in millions of dollars i...
- Initiated CALM Phase 3 program with topline data expected for CALM-1 and CALM-2 in the second half of 2024 and 2025, respectively - - Ended third quarter 2022 with US$364.4 million in cash, cash equivalents and short-term investments; Cash runway extended to the seco...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
Growth investors have exciting prospects to choose from, not in the technology sector but in healthcare, energy , and mining. BELLUS ( TSX:BLU ), Peyto Exploration & Development ( TSX:PEY ), and Perseus Mining Limited ( TSX:PRU ) have visible growth p...
The S&P/TSX Capped Health Care Index has severely underperformed the broader Canadian stock market due to a severe drag from cannabis stocks in the sub-index. However, chosen carefully, healthcare stocks may offer strong growth stock qualities, can be defensive plays during tumultuo...
Healthcare and medical technology are traditionally considered defensive sectors. That means their earnings and market value should be immune to market cycles. However, that theory has been tested this year. Most Canadian medical technology, long-term care, and healthcare service provid...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
The S&P/TSX Composite Index climbed 360 points on Friday, September 9. Every sector finished the day in the black, with battery metals, health care, and information technology sectors emerging as the standouts. That said, investors have been forced to wrestle with volatility in ...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index Canada NewsWire TORONTO , Sept. 2, 2022 /CN...
News, Short Squeeze, Breakout and More Instantly...
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
2023-06-27 18:45:00 ET Early investors in Canadian biotech stock BELLUS Health ( TSX:BLU ) could be ecstatic right now after a fine 75.5% rally in BLU stock year to date. The bullish run was ensued after global pharmaceuticals giant GSK offered to acquire all BELLUS stock at...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...